JW (Cayman) Therapeutics Co. Ltd (SEHK: 2126)
Health Care · Biotechnology · CN
HK$2.83
+5.21% today · -28.8% 1Y
JW (Cayman) Therapeutics Co. Ltd (SEHK: 2126) operates in the Biotechnology industry within the Health Care sector. The company is valued at $146.12M and employs 303 people.
Over the last twelve months the share price has lost 28.8%, trading between 1.40 and 4.50.
Tweenvest scores JW (Cayman) Therapeutics Co. Ltd across four factors: quality 40/100, value 84/100. Its strongest factor is value.
2126 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $146.12M
- Revenue (TTM)
- $42.49M
- P/E
- —
- EPS
- -0.81
- Dividend yield
- —
- Beta (5Y)
- 1.79
- 52-week high
- HK$4.50
- 52-week low
- HK$1.40
- Avg volume (3M)
- —
- Shares outstanding
- 405.90M
- Employees
- 303
- Next earnings
- —
About JW (Cayman) Therapeutics Co. Ltd
JW (Cayman) Therapeutics Co. Ltd is a clinical-stage biotechnology company dedicated to the development, manufacture, and commercialization of cell-based immunotherapies. The company primarily targets hematological cancers and solid tumors through treatments that harness the body's own immune cells to combat disease, notably including CAR-T therapies. Its leading therapeutic candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy designed to treat a variety of blood cancers. The company's innovative pipeline also features JWCAR129, an autologous CAR-T therapy for multiple myeloma; JWATM204, a TCR T-cell therapy candidate aimed at hepatocellular carcinoma (HCC); and JWATM203, another autologous T-cell receptor mimic therapy specifically targeting alpha-fetoprotein for HCC. Founded in 2016, JW (Cayman) Therapeutics Co. Ltd is headquartered in Shanghai, People's Republic of China.
- ISIN
- KYG5210T1040
- Founded
- 2016
- Listed since
- Nov 3, 2020
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Essex Bio-Technology LimitedSEHK: 1061 | $149.73M | HK$2.08 | -3.26% |
| Scancell Holdings plcAIM: SCLP | $149.18M | £0.09 | +0.54% |
| Molecular Partners AGSWX: MOLN | $148.00M | CHF3.21 | -3.60% |
| Actinogen Medical LimitedASX: ACW | $147.68M | AU$0.06 | +1.85% |
| Acumen Pharmaceuticals, Inc.NasdaqGS: ABOS | $146.08M | $2.02 | -5.61% |
| CANbridge Pharmaceuticals Inc.SEHK: 1228 | $145.79M | HK$1.92 | -6.59% |
| Kangstem Biotech Co., Ltd.KOSDAQ: A217730 | $144.47M | ₩2,065.00 | -7.81% |
| Atrium Therapeutics, Inc.NasdaqGS: RNA | $143.69M | $8.21 | -2.26% |
Figures last refreshed Oct 11, 2026.